Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 study of interferon alpha2b drug AP-003(nebuliser) for treating patients with pre-existing conditions early after COVID-19 infection

Next Previous
Trial Profile

A Phase 2 study of interferon alpha2b drug AP-003(nebuliser) for treating patients with pre-existing conditions early after COVID-19 infection

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alpha-2b (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors BetterLife Pharma

Most Recent Events

  • 21 Jan 2021 According to a BetterLife Pharma media release, company has engaged Equilab International to manage the upcoming clinical trials for its proprietary formulation of Interferon alpha2b (AP-003) in mild to moderate cases of COVID-19.
  • 27 Jul 2020 According to a BetterLife Pharma media release, the US FDA provided feedback with implementable guidance on non-clinical, CMC and clinical aspects of proposed plan to initiate clinical trial of AP 003 in COVID-2019 infections, in a pre-IND meeting. Company is anticipating to start trial in 2-3 months.
  • 23 Jul 2020 According to a BetterLife Pharma media release, the company expects that the AP-003 Phase 2 trials will be completed in the next three to six months.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top